N-[1-(4-METHYLBENZOYL)-3,5-DIMETHYLPYRAZOLE-4-YL]-4-METHYLBENZAMIDE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HQQPIXHUTAXWTA-UHFFFAOYSA-N
Smiles	Cc1ccc(cc1)C(=O)Nc2c(C)nn(C(=O)c3ccc(C)cc3)c2C
InChI	InChI=1S/C21H21N3O2/c1-13-5-9-17(10-6-13)20(25)22-19-15(3)23-24(16(19)4)21(26)18-11-7-14(2)8-12-18/h5-12H,1-4H3,(H,22,25)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H21N3O2
Molecular Weight	347.41
AlogP	4.11
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	63.99
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Anticonvulsant activity in Mus musculus Balb/c (mouse) assessed as inhibition of pentylenetetrazol-induced mortality at 100 mg/kg, ip pretreated 30 min before pentylenetetrazol challenge by pentylenetetrazol test	Mus musculus	None
Anticonvulsant activity in Mus musculus Balb/c (mouse) assessed as decrease in severity of seizure at 100 mg/kg, ip pretreated 30 min before pentylenetetrazol challenge by pentylenetetrazol test	Mus musculus	None
Anticonvulsant activity in Mus musculus Balb/c (mouse) assessed as increase in latency to seizure at 100 mg/kg, ip pretreated 30 min before pentylenetetrazol challenge by pentylenetetrazol test	Mus musculus	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2235487
PubChem	76315205

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).